Literature DB >> 7296526

Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.

J R Idle, A Mahgoub, T P Sloan, R L Smith, C O Mbanefo, E A Bababunmi.   

Abstract

The hypothesis is being explored that there may be an association between genetically determined oxidation status and propensity to develop carcinoma in response to environmental chemical carcinogens. For this purpose, the genetic structure of a normal, healthy Nigerian population with respect to oxidation status, has been compared with that found for a group of 59 Nigerian patients presenting with carcinoma of the liver and gastrointestinal tract. Genetically determined oxidation status was assessed by measuring the extent of oxidation of a probe drug, debrisoquine, to its major metabolite, 4-hydroxydebrisoquine. The cancer group contained a disproportionately large number of individuals who were extensive oxidizers compared to the controls (2 P = 0.0045). The findings support the view that genetically determined oxidation status may be an important host factor in influencing responsiveness to chemical carcinogens that require oxidative metabolic activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296526     DOI: 10.1016/0304-3835(81)90099-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Polymorphisms in oxidative drug metabolism: relationship to food preference.

Authors:  M R Britto; H E McKean; G G Bruckner; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

2.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Acetylator status of kwashiorkor children in Ibadan (south-west Nigeria).

Authors:  L H Jeyakumar; U A Arowoshegbe; O O Akinyinka; F O Akinbami; E A Bababunmi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jan-Mar       Impact factor: 2.441

4.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

Review 5.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

6.  The genetic control of phenformin 4-hydroxylation.

Authors:  R R Shah; D A Evans; N S Oates; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1985-10       Impact factor: 6.318

Review 7.  Passively inhaled tobacco smoke: a challenge to toxicology and preventive medicine.

Authors:  H Remmer
Journal:  Arch Toxicol       Date:  1987-12       Impact factor: 5.153

8.  Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer.

Authors:  Y Horai; K Fujita; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

Authors:  J M Ladero; J Benítez; J F González; E Vargas; M Díaz-Rubio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Acetylation and oxidation phenotypes in malignant lymphoma.

Authors:  P A Philip; H J Rogers; P G Harper
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.